Latest news and insights on the pharmaceutical industry | Indian Pharma Post | Page 53

Results For "EDS"

1512 News Found

Moderna pauses plan to build mRNA manufacturing facility in Kenya
News | April 16, 2024

Moderna pauses plan to build mRNA manufacturing facility in Kenya

The demand in Africa for COVID-19 vaccines has declined


Novartis reports data from trial of IgA nephropathy treatment
Clinical Trials | April 16, 2024

Novartis reports data from trial of IgA nephropathy treatment

IgAN is a heterogeneous, progressive, rare kidney disease and is a major cause of chronic kidney disease worldwide


Suven Life Sciences to present phase-2 results on Samelisant at AAN 2024
Clinical Trials | April 16, 2024

Suven Life Sciences to present phase-2 results on Samelisant at AAN 2024

Global Phase-3 study initiation expected in the second half of 2024


Croda and AAHI partner to drive innovation in vaccine development
News | April 15, 2024

Croda and AAHI partner to drive innovation in vaccine development

The exclusive agreement between AAHI and Croda includes a collaborative effort in research and development


Syntegon showcases oral solid dosage portfolio at Achema
News | April 11, 2024

Syntegon showcases oral solid dosage portfolio at Achema

Fluid bed processes: drying, granulating, and coating in just one product container


Asahi Kasei Bioprocess and Axolabs partner to accelerate oligonucleotide therapeutics development
News | April 11, 2024

Asahi Kasei Bioprocess and Axolabs partner to accelerate oligonucleotide therapeutics development

The partners will collaborate to build a cutting-edge oligonucleotide cGMP manufacturing facility


President Murmu to inaugurate homeopathic symposium on World Homoeopathy Day 2024
News | April 10, 2024

President Murmu to inaugurate homeopathic symposium on World Homoeopathy Day 2024

Empowering Research, Enhancing Proficiency is the theme of this year’s Homoeopathic Symposium


Pluss unveils Celsure XL VIP pallets
News | April 07, 2024

Pluss unveils Celsure XL VIP pallets

A game changing solution for the pharmaceutical industry


USFDA approves Bristol Myers and 2seventy bio’s Abecma for triple-class exposed multiple myeloma
Drug Approval | April 06, 2024

USFDA approves Bristol Myers and 2seventy bio’s Abecma for triple-class exposed multiple myeloma

Abecma tripled progression-free survival compared to standard regimens in the Phase 3 KarMMa-3 trial